Immunomodulating Agents: all 61 studies that test it

Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression DisorderNot yet recruitingNCT07812181Phase 2
• Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCNot yet recruitingNCT07782242Phase 4
• Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruitingNCT07680946Phase 2
• A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)RecruitingNCT07673744Phase 2
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)RecruitingNCT07503873Phase 2
• Etrasimod as Prevention of PouchitisRecruitingNCT07486921Phase 2
• A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisRecruitingNCT07470879Phase 2
• Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisRecruitingNCT07389590Phase 4
• Ublituximab (Briumvi) for Early Forms of Relapsing Multiple SclerosisRecruitingNCT07225361Phase 4
• Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingNCT07220252Phase 2/3
• Ublituximab in Autoantibody Positive Immune Mediated Necrotizing MyopathyRecruitingNCT07103746Phase 2
• Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisRecruitingNCT06864936Not applicable
• Effects of Ublituximab on Motor Functions in Multiple SclerosisRecruitingNCT06629428Early Phase 1
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabRecruitingNCT05877963Phase 3
• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisRecruitingNCT05287126Phase 2
• A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by InjectionTerminatedNCT05732454Phase 2/3Results posted
• Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT05061446Phase 2Results posted
• Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04783415Phase 2Results posted
• Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)CompletedNCT04706793Phase 3Results posted
• Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedNCT04692155Phase 1/2Results posted
• A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic EsophagitisCompletedNCT04682639Phase 2Results posted
• Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingNCT04624633Phase 2Results posted
• Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative ColitisCompletedNCT04607837Phase 2Results posted
• Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia AreataCompletedNCT04556734Phase 2Results posted
• Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone LymphomaCompletedNCT04508647Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's DiseaseTerminatedNCT04173273Phase 2/3Results posted
• A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic DermatitisCompletedNCT04162769Phase 2Results posted
• Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedNCT04149821Phase 2Results posted
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisCompletedNCT03996369Phase 3Results posted
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisCompletedNCT03945188Phase 3Results posted
• Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedNCT03828448Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedNCT03801525Phase 2/3Results posted
• Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )CompletedNCT03277261Phase 3Results posted
• Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)CompletedNCT03277248Phase 3Results posted
• Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary CholangitisTerminatedNCT03155932Phase 2Results posted
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal ManifestationsTerminatedNCT03139032Phase 2Results posted
• Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumTerminatedNCT03072953Phase 2Results posted
• Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple SclerosisCompletedNCT02738775Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedNCT02656303Phase 2Results posted
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT02612311Phase 3Results posted
• Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT02536404Phase 2Results posted
• Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative ColitisCompletedNCT02447302Phase 2Results posted
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)CompletedNCT02301156Phase 3Results posted
• Ublituximab for Acute Neuromyelitis Optica (NMO) RelapsesCompletedNCT02276963Phase 1Results posted
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT07211633Phase 3
• A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding WomenCompletedNCT07153159Phase 1
• Etrasimod for Immune Checkpoint Inhibitor Diarrhea and ColitisWithdrawnNCT06521762Phase 2
• Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnNCT05152459Phase 1/2
• Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
• A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT04176588Phase 3
• An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisActive, not recruitingNCT04130997Phase 3
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT03950232Phase 3
• Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaTerminatedNCT03778073Phase 1
• Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCTActive, not recruitingNCT03455972Phase 1/2
• An Extension of the TG1101-RMS201 TrialCompletedNCT03381170Phase 2
• Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 TrialsTerminatedNCT03207256Phase 2
• Ublituximab + Ibrutinib in Select B-cell MalignanciesCompletedNCT02013128Phase 1/2
• Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
• Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
• Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT01647971Phase 1/2
• LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic LeukemiaCompletedNCT01098188Phase 1

← Immunomodulating Agents overview